CEO ONAKids

Barcelona, Spain Call4Entrepreneurs - The ColliderRevise detenidamente toda la documentación de la solicitud antes de hacer clic en el botón de solicitar al final de esta descripción.About the job CEO ONAKids (The Collider Programme)ONAkids | Early Screening for Language Development DisordersAre you seeking a new entrepreneurial adventure in health innovation with the opportunity to build a high-impact medtech spin-off?ONAkids , project developed at the Brainlab Cognitive Neuroscience Research Group (Universitat de Barcelona) with the support of Fundació Bosch i Gimpera, is looking for an entrepreneurial profile with strong business acumen and founder experience to join the team.As the Entrepreneur, you will be part of our venture-building journey, leading thebusiness validation phasehand-in-hand with the scientific team. At the end of this process, if the business and the team are validated, the spin-off will be incorporatedand you will become theCEO & Co-Founderof a disruptive medical device company transforming neonatal health.About ONAkidsLanguage delay affects1 in 5 childrenand is associated with long-term difficulties in reading, attention, socialization and mental health. Early detection significantly improves outcomes but today, no neonatal screening tool reliably identifies this risk.ONAkids has developed an EEG-based medical devicethat records newborns brain responses to speech sounds and, through cloud-based AI models, provides80% prediction accuracyfor language-development riskenabling early intervention within the first months of life.The team vision is to position ONAkids as auniversal newborn screening tool , comparable in simplicity and cost to current mandatory hearing tests.Main project achivements so far:ValidatedAI algorithmsreaching80% accuracy.A protected database of600 neonatal EEG recordings, with longitudinal follow-up available for approximately 200 cases.Adedicated prototype devicedesigned for neonatal clinical use.Consistent competitive funding since 2021, securing a total of 400,000 including MICINN, AGAUR, Biocat and CRAASH.The Entrepreneur will play a critical role in advancing ONAkids by bringing business leadership, regulatory awareness, and strategic execution to build a viable, clinically validated and scalable medical device company. Key challenges include:Defining thevision, financial model and business strategyfor the future spin-off.Leadingpatient journey definitionand selecting thebeachhead market.Coordinatingclinical validation , regulatory pathways ( CE/MDR; FDA desirable ) and market access.Securing the firstclinical pilotsand early adopters.Leading the firstfundraising rounds(public and private).Managing day-to-day operations and executing the commercial roadmap.The OfferRelevant equityas CEO and Co-Founder once the company is established.6,000 stipend(3 monthly instalments of 2,000 each).Opportunity to access aparticipative loan of up to 50Kto finance the first phases of the project.International exposurethrough The Collider ecosystem (4YFN, Mobile World Congress, corporate & investor networks).Access toa structured programmesupported by mentors, specialists, healthcare experts, industry partners and investors.Coworking spacein Barcelona (Tech Barcelona Pier 01).Backing from theUniversitat de Barcelona , Fundació Bosch i Gimpera, and a highly respected scientific team.This opportunity is for you If:You are an entrepreneur with experience founding or co-foundinghealthtech/medtech/digital healthstartups.Passionate aboutscience-based innovation , child health and preventative care.Skilled instrategy, leadership, fundraising, and market access.Familiar with medical device development:clinical validation, regulation (MDR/CE), industrialization, go-to-marketExperienced in securingpublic grantsandprivate investment.A resilient, hands-on leader capable of bridgingscience, clinical practice and business.Eligible to work in Spain (passport or visa required).Fluent in English andSpanish; Catalan is a plus. xsgfvud About the ProgrammeFounded in 2017,The Colliderhas supported more than200 scientific projects , created23 deep-tech spin-offs , and manages a portfolio valued at112M , with a 77% survival rate.#J-18808-Ljbffr